trial

Memantine as Adjunctive Therapy for Schizophrenia Negative Symptoms

NCTId NCT00757978
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 22 (actual)
Sponsored by Hospital de Clinicas de Porto Alegre
Primary completion 2008-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
22 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2006-01
Primary completion
2008-01
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Memantine

Sponsors

Hospital de Clinicas de Porto AlegreLead Sponsor

Investigators

1
Clarissa S Gama, MD, PhDStudy Director

Sites

1 total
Porto Alegre, Brazil

Facts & assertions

4 sourced
Enrollment
22
Phase
PHASE4
Primary Completion Date
2008-01
Status
COMPLETED
relationships
The graph out of here
drug
Memantine
drug
lead_sponsor
Hospital de Clinicas de Porto Alegre
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Clarissa S Gama, MD, PhD
person